Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory, recurrent, or metastatic ovarian or cervical cancer.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Study of Prolonged Oral VP-16 for Advanced Ovarian Epithelial and Cervical Cancer|
|Study Start Date:||June 1993|
|Primary Completion Date:||October 2003 (Final data collection date for primary outcome measure)|
OBJECTIVES: I. Determine the efficacy of prolonged oral etoposide (VP-16) in patients with advanced ovarian epithelial or cervical cancer. II. Evaluate the frequency and severity of observed adverse effects in this patient population treated with prolonged oral VP-16.
OUTLINE: Patients receive etoposide by mouth once daily on days 1-21 every 4 weeks. Patients with responding disease continue treatment for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease continue treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: If 4-6 responses are observed in the first 25 patients, an additional 15 patients will be entered. The estimated duration of the study is 8 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002478
Show 47 Study Locations
|Study Chair:||Peter G. Rose, MD||University Hospitals Seidman Cancer Center|